BioCentury | Aug 9, 2017
Distillery Techniques

Drug properties

TECHNOLOGY: Physicochemical properties Formulations based on combinations of amino acids, sugars and emulsifiers could enable long-term, low-viscosity storage of high-concentration antibodies. Formulations of low (50 mg/mL), high (150 mg/mL) and ultra-high (175 mg/mL) concentrations of...
BioCentury | Mar 2, 2015
Clinical News

Mirogabalin: Phase III started

Daiichi Sankyo began the international Phase III ALDAY program comprising 3 double-blind, placebo-controlled trials and an open-label extension safety study of 15 mg oral mirogabalin given once or twice daily in about 4,000 patients. The...
BioCentury | Jan 2, 2012
Clinical News

Northera droxidopa: Phase II data

Top-line data from the double-blind, U.K. Phase II FMS201 trial in 120 patients showed that thrice-daily 600 mg oral droxidopa alone led to a 6.2 point improvement from baseline on the SF-MPQ at week 9,...
BioCentury | Aug 15, 2011
Company News

biOasis deal

...but not less that C$0.50. biOasis' CogniTest , an Alzheimer's diagnostic melanoma-associated antigen p97 ( MFI2 ; CD228...
BioCentury | Aug 15, 2011
Clinical News

Northera droxidopa: Completed Phase II enrollment

Chelsea completed enrollment of 120 patients in the double-blind, U.K. Phase II FMS201 trial. The 12-arm study is evaluating 200, 400 or 600 mg of oral droxidopa given 3 times daily; 25 or 50 mg...
BioCentury | Aug 30, 2010
Clinical News

Northera droxidopa: Phase II started

Researchers began an open-label, U.S. Phase II trial to evaluate up to 600 mg oral droxidopa given thrice daily for 14 weeks in about 20 patients. Chelsea has rights to droxidopa outside of Japan, Korea,...
BioCentury | Jul 5, 2010
Clinical News

Northera droxidopa: Phase II ongoing

An independent DMC recommended continuation of enrollment in 7 of 12 arms of a double-blind, U.K. Phase II trial. Enrollment will continue in cohorts receiving 50 mg oral carbidopa; 600 mg oral droxidopa; 400/25 mg,...
BioCentury | Feb 2, 2009
Clinical News

Droxidopa: Phase II started

Chelsea began a double-blind, U.K. Phase II trial in 120 patients. The 12-arm study is designed to evaluate 200, 400 or 600 mg of oral droxidopa given 3 times daily; 25 or 50 mg carbidopa...
BioCentury | Jul 28, 2008
Clinical News

Droxidopa: Phase II start

In late September, Chelsea plans to start a double-blind, placebo-controlled, U.K. Phase II trial in 120 patients. The 12-arm study is designed to evaluate 200, 400 or 600 mg of oral droxidopa given 3 times...
Items per page:
1 - 9 of 9